4O04
Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease
Summary for 4O04
Entry DOI | 10.2210/pdb4o04/pdb |
Related | 4O05 4O06 4O09 4O0B |
Descriptor | Heat shock protein HSP 90-alpha, 4-(2,7,7-trimethyl-5-oxo-1,2,3,4,5,6,7,8-octahydro-9H-beta-carbolin-9-yl)benzamide (3 entities in total) |
Functional Keywords | chaperone, chaperone-chaperone inhibitor complex, chaperone/chaperone inhibitor |
Biological source | Homo sapiens (human) |
Cellular location | Cytoplasm : P07900 |
Total number of polymer chains | 1 |
Total formula weight | 26534.84 |
Authors | Zuccola, H.J.,Ernst, J. (deposition date: 2013-12-13, release date: 2014-12-24, Last modification date: 2024-02-28) |
Primary citation | Ernst, J.T.,Neubert, T.,Liu, M.,Sperry, S.,Zuccola, H.,Turnbull, A.,Fleck, B.,Kargo, W.,Woody, L.,Chiang, P.,Tran, D.,Chen, W.,Snyder, P.,Alcacio, T.,Nezami, A.,Reynolds, J.,Alvi, K.,Goulet, L.,Stamos, D. Identification of Novel HSP90 alpha / beta Isoform Selective Inhibitors Using Structure-Based Drug Design. Demonstration of Potential Utility in Treating CNS Disorders such as Huntington's Disease. J.Med.Chem., 57:3382-3400, 2014 Cited by PubMed: 24673104DOI: 10.1021/jm500042s PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.82 Å) |
Structure validation
Download full validation report